Clinical Study
Testing the Treatment of Donor Cell Transplants for Children and Young Adults with Severe Myeloid Leukemia
This study is testing the treatment with Natural Killer cells from a donor to a patient, which may lower the chance that a blood disease severe myeloid leukemia will come back after a haploidentical (half-matched) transplant (moving cells from a donor to a patient). The study wants to see if the treatment will help people with severe myeloid leukemia. People in the study will receive Natural Killer cells from a central line placed in the body, most likely the chest. A central line is a tube that allows medications, medical tests, and transfusions to occur. Transfusion is a way to move blood from a donor to a patient. Being in the study requires attending in-person study visits at a clinic for about 2 years. Medical tests will be done to track the health of participants.
For more information contact:
Karely van Thiel Berghuijs
karely.vanthiel@hci.utah.edu
801-864-5837
IRB#: IRB_00152764
| PI: Greg Dolan
| Department: PEDIATRIC HEMATOLOGY/ONCOLOGY
| Approval Date: 2022-12-07 07:00:00
Study Categories: All Cancer Studies
| Specialties: Pediatric Hematology & Oncology
Who can participate?
Gender: All
Age: All Ages
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Patients ages 4 months to 25 years old and donors ages 18 years and older
- Patient diagnosis of severe myeloid leukemia
- Patient recovery from a prior cycle of chemotherapy (a way to treat a disease such as cancer)
- Patients major organs (lung, heart, kidneys) function
- Donor matches specific criteria for the patient to receive the treatment
Exclusion Criteria:
- Patient has ongoing serious infections
- Patient is pregnant
- Patient has prior cell transplant
- Patients with other specific genetic diseases
- Donor unable to stop medication that may affect the treatment
Will I be paid for my time?
No